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ORIGINAL RESEARCH
Acetaminophen (Paracetamol) Metabolites 
Induce Vasodilation and Hypotension  
by Activating Kv7 Potassium Channels  
Directly and Indirectly
Jennifer van der Horst, Rian W. Manville, Katie Hayes, Morten B. Thomsen, Geoffrey W. Abbott, Thomas A. Jepps
OBJECTIVE: Intravenous acetaminophen/paracetamol (APAP) is well documented to cause hypotension. Since the patients 
receiving intravenous APAP are usually critically ill, any severe hemodynamic changes, as with those associated with APAP, 
can be life-threatening. The mechanism underlying this dangerous iatrogenic effect of APAP was unknown.
APPROACH AND RESULTS: Here, we show that intravenous APAP caused transient hypotension in rats, which was attenuated by 
the Kv7 channel blocker, linopirdine. APAP metabolite N-acetyl-p-benzoquinone imine caused vasodilatation of rat mesenteric 
arteries ex vivo. This vasodilatation was sensitive to linopirdine and also the calcitonin gene-related peptide antagonist, BIBN 
4096. Further investigation revealed N-acetyl-p-benzoquinone imine stimulates calcitonin gene-related peptide release from 
perivascular nerves, causing a cAMP-dependent activation of Kv7 channels. We also show that N-acetyl-p-benzoquinone 
imine enhances Kv7.4 and Kv7.5 channels overexpressed in oocytes, suggesting that it can activate Kv7.4 and Kv7.5 channels 
directly, to elicit vasodilatation.
CONCLUSIONS: Direct and indirect activation of Kv7 channels by the APAP metabolite N-acetyl-p-benzoquinone imine decreases 
arterial tone, which can lead to a drop in blood pressure. Our findings provide a molecular mechanism and potential preventive 
intervention for the clinical phenomenon of intravenous APAP-dependent transient hypotension.
Key Words: acetaminophen ◼ hypotension ◼ linopirdine ◼ potassium channels ◼ vasodilation
Acetaminophen/paracetamol (APAP) is the most frequently used analgesic worldwide and the most common drug ingredient used in the United States, 
with a presence in over 600 medications. Orally admin-
istered APAP can increase blood pressure when used 
often.1–3 In contrast, APAP is well documented to cause 
severe and sometimes fatal hypotension in patients when 
administered intravenously, such as is common in surgi-
cal intensive care units.4–8 Although >33% of patients 
that had APAP-induced hypotension required therapeu-
tic intervention,6,9 the mechanisms underlying the severe 
hemodynamic changes during intravenous APAP admin-
istration are still unknown.4
APAP’s analgesic mechanism of action is regarded to 
be through COX (cyclooxygenase) inhibition10; however, 
this hypothesis has come under scrutiny since APAP 
lacks the adverse effects of NSAIDs that are associ-
ated with COX inhibition. Novel targets of certain APAP 
metabolites have been identified to underlie its analge-
sic effects. N-acetyl-p-benzoquinone imine (NAPQI) and 
N-arachidonoylphenolamine (AM404) are 2 such metab-
olites of APAP identified to activate transient receptor 
potential ankyrin 1 channel and transient receptor poten-
tial vanilloid 1 channel (TRPV1), which were associated 
with its antinociceptive effects.11–13 Furthermore, NAPQI 
was identified recently to enhance the activity of the 
D
ow
nloaded from
 http://ahajournals.org by on March 30, 2020
OR
IG
IN
AL
 R
ES
EA
RC
H 
- V
B
van der Horst et al Acetaminophen Metabolites Activate Kv7 Channels
2  May 2020 Arterioscler Thromb Vasc Biol. 2020;40:00–00. DOI: 10.1161/ATVBAHA.120.313997
neuronal voltage-gated Kv7 potassium channels, Kv7.2 
and Kv7.3 in dorsal root ganglion and spinal dorsal horn 
neurons.14 By enhancing Kv7 channel activity, NAPQI 
hyperpolarised the membrane potential and reduced 
action potential firing, which might underlie the analgesic 
action of APAP as well as contributing to APAPs recently 
discovered anticonvulsant properties.14,15
Because Kv7 channels are important regulators of 
arterial tone,16–21 we hypothesized that APAP-induced 
hypotension was due to APAP metabolites activating 
Kv7 channels, thereby causing vasodilation and a drop 
in blood pressure. Here, we provide in vivo, ex vivo, and 
in vitro evidence that APAP metabolites can cause hypo-
tension and relax arteries by activating Kv7 channels 
directly and indirectly.
MATERIALS AND METHODS
Disclosure Statement
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Animals
To avoid the potential confounding effects of sex-specific Kv7 
channel function in the vasculature22 that are still not under-
stood, male Wistar rats (Janvier Labs, France) aged 12 to 14 
weeks were used in accordance with Directive 2010/63EU 
on the protection of animals used for scientific purposes and 
approved by the national ethics committee, Denmark. Rats 
were group-housed with regular 12-hour light/dark cycles, 
in clear plastic containers with ad libitum access to food and 
water, and underwent at least 1 week of habituation.
Surgical Preparation for Rat In Vivo 
Experiments
In vivo experiments were performed on 12-week-old male 
Wistar rats (300–400 g). The rats were anesthetized with 
5% isoflurane delivered in 35% oxygen and 65% nitrogen, 
intubated and connected to a respirator (≈65 breaths/min; 
tidal volume 8 mL/kg). The left carotid artery was cannulated 
with a catheter connected to a pressure transducer (Statham 
P23-dB) for continuous monitoring of the arterial blood 
pressure. The left jugular vein was cannulated to allow for 
continuous infusion of a muscle relaxant, cisatracurium (0.85 
mg/mL), and saline infusion or intravenous administration of 
the drugs. The rat was placed on a heating plate to maintain 
body temperature at 37°C and the trachea was. After sur-
gery, the anesthesia was maintained at 2% isoflurane, and the 
rat was allowed to rest for 30 minutes before initiating the 
experimental protocol. After the experimental protocol, the rat 
was euthanized.
Experimental Protocol for In Vivo Rat 
Experiments
After the 30-minute rest period and obtaining a stable blood 
pressure baseline, APAP was infused at 0.33 mg/min for 15 
minutes to give a total dose of 4.95 mg of APAP, equivalent 
to 14.14 mg/kg in a 350 g rat, which corresponds to a 70 kg 
human receiving 1 g of APAP. Hereafter, another 30-minute 
recovery period under infusion of saline was initiated to recover 
the blood pressure to baseline. Subsequently, the Kv7 channel 
blocker linopirdine (0.9 mg/min) was preinfused for 10 min-
utes, followed by coinfusion of linopridine (0.9 mg/min) and 
APAP (0.33 mg/min) for another 15 minutes. The infusion rate 
of the saline and drugs, including cisatracurium, was constant 
throughout the experiment at 40 µL/min.
Channel Subunit cRNA Preparation and 
Xenopus laevis Oocyte Injection
cRNA transcripts encoding human Kv7.4 and Kv7.5 were gen-
erated by in vitro transcription using the T7 polymerase mMes-
sage mMachine kit (Thermo Fisher Scientific), after vector 
linearization, from cDNA and subcloned into plasmids incorpo-
rating X. laevis β-globin 5′ and 3′ UTRs flanking the coding 
region to enhance translation and cRNA stability. We quantified 
cRNA by spectrophotometry. Defolliculated stage V and VI X. 
laevis oocytes (Xenoocyte, Dexter, MI) were injected with Kv7.4 
or Kv7.5 cRNA (20 ng total per oocyte). Oocytes were incubated 
at 16°C in Barth’s saline solution (Ecocyte Bioscience, Austin, 
TX) containing penicillin and streptomycin and washed daily for 
3 to 5 days before 2-electrode voltage-clamp recording.
Nonstandard Abbreviations and Acronyms
AM404 N-arachidonoylphenolamine
APAP acetaminophen/paracetamol
CGRP calcitonin gene-related peptide
COX cyclooxygenase
CYP cytochrome P450
NAPQI N-acetyl-p-benzoquinone imine
TRPV1  transient receptor potential vanilloid 1 
channel
Highlights
• Intravenous acetaminophen administration causes 
transient hypotension in the clinic but the mecha-
nism responsible for this iatrogenic effect was 
unknown.
• We show that the metabolite, N-acetyl-p-
benzoquinone imine, is a potent vasodilator, which 
can activate Kv7.4 and Kv7.5 channels directly. 
We also discovered that N-acetyl-p-benzoquinone 
imine can induce release of calcitonin gene–related 
peptide from perivascular nerves, which causes 
relaxation of smooth muscle cells, in part, through 
the activation of Kv7 channels.
• Thus, we provide novel molecular insight to explain 
how intravenous acetaminophen administration 
causes transient hypotension and suggest a pos-
sible therapeutic solution.
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Isometric Tension Recordings
Rats were euthanized by cervical dislocation, and third-order 
mesenteric arteries were isolated and mounted in a wire myo-
graph (Danish Myo Technology, Aarhus Denmark) for isometric 
tension recording, as described previously.20 Briefly, arterial seg-
ments were removed from the animals and cleaned of adherent 
tissue in physiological salt solution (PSS) containing (in mM): 
121 NaCl, 2.8 KCl, 1.6 CaCl2, 25 NaHCO3, 1.2 KH2HPO4, 1.2 
MgSO4, 0.03 EDTA, and 5.5 glucose. Following dissection, ves-
sels were cut into 2 mm segments and mounted on 40 µm 
stainless steel wires in a myograph for isometric tension record-
ings. The chambers of the myograph contained PSS maintained 
at 37°C and aerated with 95% O2/5% CO2. Changes in tension 
were recorded continuously by PowerLab and Chart software 
(ADInstruments, Oxford, United Kingdom). The arteries were 
equilibrated for 30 minutes and normalized to passive force.23
Arteries were contracted with 20 µM α1-adrenergic recep-
tor agonist, methoxamine, before increasing concentrations of 
APAP (1.0–100 µM), NAPQI (0.1–10 µM) or AM404 (0.1–30 
µM) were added to vessels in the absence or presence of the Kv7 
channel blocker, linopirdine (10 µM). The effects of NAPQI and 
AM404 were also tested on preconstricted segments of mesen-
teric arteries in the presence of the calcitonin gene-related pep-
tide (CGRP) receptor antagonist, BIBN 4096 (1 µM) or TRPV1 
channel blocker AMG9810 (0.1 µmol/L). Furthermore, NAPQI 
relaxations were tested after repeated capsaicin (10 µM) stimu-
lations to deplete CGRP levels. To test the effects of NAPQI 
and AM404 on contractions elicited by high external potassium, 
the PSS was replaced with a high potassium solution containing 
(in mM): 123.7 KCl, 1.6 CaCl2, 25 NaHCO3, 1.2 KH2HPO4, 1.2 
MgSO4, 0.03 EDTA, and 5.5 glucose. Once a stable contraction 
was achieved, either NAPQI or AM404 was applied.
Two-Electrode Voltage-Clamp
Two-electrode voltage-clamp was performed at room tempera-
ture using an OC-725C amplifier (Warner Instruments, Hamden, 
CT) and pClamp11 software (Molecular Devices, Sunnyvale, 
CA) 3 to 5 days after cRNA injection as described in the section 
above. For recording, oocytes were placed in a small-volume 
oocyte bath (Warner) and viewed with a dissection microscope. 
Bath solution was (in mM): 96 NaCl, 4 KCl, 1 MgCl2, 1 CaCl2, 
10 HEPES (pH 7.6). NAPQI and AM404 were solubilized in 
dimethyl sulfoxide (DMSO) and diluted to working concentra-
tions each experimental day. NAPQI and AM404 were intro-
duced into the oocyte recording bath by gravity perfusion at a 
constant flow of 1 mL per minute for 3 minutes before record-
ing. Pipettes were of 1 to 2 MΩ resistance when filled with 
3 M KCl. We recorded currents in response to voltage pulses 
between −120 or −80 mV and +40 mV at 20 mV intervals 
from a holding potential of −80 mV, to yield current-voltage rela-
tionships, current magnitude, and for quantifying activation rate. 
Electrophysiology data analysis was performed with Clampfit 
(Molecular Devices) and Graphpad Prism software (GraphPad, 
San Diego, CA); values are stated as mean±SEM. Raw or nor-
malized tail currents were plotted versus prepulse voltage and 
fitted with a single Boltzmann function (Equation 1):
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where g is the normalized tail conductance, A1 is the ini-
tial value at −∞, A2 is the final value at +∞, V1/2 is the half-
maximal voltage of activation and versus the slope factor. We 
fitted activation and deactivation kinetics with single exponen-
tial functions. Based on our previous studies of Kv7 channel 
pharmacology using the oocyte expression21 system, the homo-
geneity, stability, and reproducibility of the system with respect 
to recordings of drug effects compared to an internal refer-
ence, baseline recording from the same oocyte means that the 
variability is minimal and n≥5 gives an accurate representation 
allowing conclusions to be made.
Chemicals and Reagents
APAP, AM404, NAPQI, linopirdine, methoxamine, indometha-
cin, and capsaicin were purchased from Sigma-Aldrich (Søborg, 
Denmark). CGRP (rat), glibenclamide, AMG9810, and BIBN 
4096 were purchased from Tocris (United Kingdom). Stock 
solutions of APAP, AM404, NAPQI, linopirdine BIBN 4096, 
glibenclamide, indomethacin, AMG9810, and capsaicin were 
prepared in DMSO. Methoxamine and CGRP were prepared 
in Milli-Q water.
Statistics
All data passed the F test for equal variance and with no sphe-
ricity assumed. Normality was not assessed as the n values 
were too low for an accurate D’Agostino and Pearson test. In 
2-electrode voltage-clamp experiments, the changes in mem-
brane potential (EM) were compared with a Student unpaired t 
test. Maximum relaxation (Rmax) and EC50 values from the iso-
metric tension experiments were compared by either a Student 
unpaired t test or 1-way ANOVA followed by a Tukey or Dunnett 
multiple comparison test. For the in vivo experiments, changes 
in mean, systolic and diastolic arterial pressures, and heart rate 
and pulse pressure were compared by a Wilcoxon matched-
pairs signed-rank test. All data are mean±SEM.
RESULTS
Intravenous APAP Causes Hypotension in Rats, 
Which Is Attenuated by Kv7 Channel Inhibition
Although there are inherent differences in human and rat 
metabolism, as well as differences in the ratios of total 
water to total plasma levels, we attempted to administer a 
dose of APAP to the anesthetized rats that corresponds 
to that given to humans. In humans, typical intravenous 
doses for APAP are of the order of 1 g, which for a 70 
kg person would equate to 14.28 mg/kg. Thus, in the 
rats, which had an average weight of 350 g, we admin-
istered 0.33 mg/min for 15 minutes to give a dose of 
14.12 mg/kg and a total of 4.95 mg of APAP. APAP 
induced a transient drop in mean arterial pressure from 
97±4 mm Hg to 79±4 mm Hg (n=7; P=0.015 according 
to a Wilcoxon matched-pairs signed-rank test; Figure 1). 
APAP did not affect the heart rate (340±13 bpm before 
versus 333±13 bpm during APAP-induced hypotension) 
or pulse pressure (28±5 mm Hg before versus 30±7 
mm Hg during APAP-induced hypotension).
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To determine if the APAP-induced hypotension could 
be prevented by Kv7 channel inhibition, we preinfused 
linopirdine at 39.1 mg/mL for 10 minutes, before coin-
fusion of linopridine (0.9 mg/min), and APAP (0.33 
mg/min). Under these conditions, APAP still decreased 
mean arterial pressure from 90±5 mm Hg to 85±4 
mm Hg (n=7); however, this decrease in mean arterial 
pressure was much smaller compared with that in the 
absence of linopirdine (−5±1 mm Hg versus −18±2 
mm Hg; P=0.015 according to a Wilcoxon matched-pairs 
signed-rank test; Figure 1). APAP-induced decreases 
in systolic and diastolic arterial pressures were also 
Figure 1. Intravenous acetaminophen/paracetamol (APAP) decreases mean arterial pressure (MAP), systolic arterial pressure 
(SAP), and diastolic arterial pressure (DAP), which linopirdine attenuated.
A, MAP (i), SAP (ii), and DAP (iii) are decreased in anesthetized rats infused with APAP intravenously (n=7). This effect is inhibited by the 
preinfusion and coinfusion of linopirdine for MAP, SAP, and DAP (according to a Wilcoxon matched-pairs signed-rank test, with *P<0.05). B, 
Pulse pressure (i) and heart rate (ii) were not different between groups (n=7).
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attenuated by preinfusion and coinfusion of linopirdine 
(Figure 1). Linopirdine had no effect on the heart rate 
or pulse pressure during preinfusion or coinfusion with 
APAP (Figure 1).
APAP Has No Effect on Tone in Rat Mesenteric 
Arteries
Application of increasing concentrations of APAP to rat 
mesenteric arteries preconstricted with methoxamine 
caused a diminutive relaxation at 100 µmol/L, which 
was not affected by the Kv7 channel blocker, 10 µmol/L 
linopirdine (n=7; Figure 2).
NAPQI Relaxes Mesenteric Artery Segments
We applied increasing concentrations of NAPQI to mes-
enteric artery segments preconstricted with methoxamine 
(Figure 3). NAPQI caused vasorelaxation of the arte-
rial segments (n=14), which was inhibited by pretreat-
ment with 10 µmol/L linopirdine (n=9; Rmax P=0.0004 
according to an unpaired Student t test; Figure 3). 
Application of 10 µmol/L NAPQI in high K+-containing 
PSS had no effect (Figure I in the Data Supplement). To 
determine whether the NAPQI relaxations were due to 
COX inhibition, we performed experiments in the pres-
ence of the COX inhibitor indomethacin. Application of 
10 µmol/L indomethacin had no effect on NAPQI relax-
ations (n=7; Figure II in the Data Supplement).
NAPQI Stimulates CGRP Release From 
Perivascular Nerves
NAPQI can activate transient receptor potential ankyrin 
1 channel and TRPV1, which are found on perivascu-
lar nerves and induce release of calcitonin gene-related 
peptide (CGRP), a potent vasodilator.24 We, therefore, 
investigated whether the relaxation to NAPQI was attrib-
utable to CGRP release from the perivascular nerves.
Direct inhibition of the CGRP receptor with 1 µmol/L 
BIBN 4096 (n=7) attenuated the NAPQI-induced vasore-
laxations (control n=14; EC50 P<0.0001 according to an 
unpaired Student t test; Figure 4). At 10 µmol/L, NAPQI 
was able to relax the arterial segments in the presence of 
BIBN 4096, although this relaxation was still attenuated 
compared to control (Rmax P=0.033 according to a 1-way 
ANOVA followed by a Tukey multiple comparisons test; 
Figure 4). When BIBN 4096 was applied with linopirdine 
Figure 2. Acetaminophen/paracetamol (APAP) has no effect on preconstricted mesenteric arteries.
A, Representative isometric tension recordings showing the effect of increasing concentrations of APAP in rat mesenteric arteries preconstricted 
with 10 µmol/L methoxamine (•) in the (i) absence and (ii) presence of the Kv7 channel inhibitor, linopirdine (10 µmol/L). B, Mean data showing 
the effect of APAP (n=7) and APAP in the presence of linopirdine (n=7) on the tension of preconstricted mesenteric arteries.
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(n=7), the relaxation to NAPQI was abolished completely 
(Rmax P<0.0001 according to a 1-way ANOVA followed 
by a Tukey multiple comparisons test; Figure 4).
To confirm that the BIBN 4096-sensitive relaxations 
were due to CGRP release from the perivascular nerves, 
we depleted CGRP from the perivascular nerves using 
the TRPV1 activator, capsaicin. After repeated capsaicin 
stimulations, we precontracted the arterial segment, con-
firmed that capsaicin was unable to relax the artery, and 
applied increasing concentrations of NAPQI (n=7; Fig-
ure 5). The effect of NAPQI after capsaicin stimulations 
was the same as in the presence of BIBN 4096 (NAPQI 
EC50 for BIBN 4096 versus capsaicin was −5.36±0.07 
versus −5.36±0.03; P=0.99 according to a 1-way 
ANOVA followed by a Tukey multiple comparisons test; 
Figure 5). When we performed the capsaicin experiments 
in the presence of BIBN 4096, there was no effect on 
the NAPQI relaxations observed with capsaicin alone 
(Figure 5). We also confirmed this pathway by inhibiting 
the TRPV1 channel with AMG9810 to prevent NAPQI 
from stimulating this channel, thereby provoking CGRP 
release (Figure 5). The relaxations to NAPQI in the pres-
ence of 0.1 µmol/L AMG9810 (EC50=−5.6±0.16; n=7; 
P=0.0095 compared with control according to a 1-way 
ANOVA followed by a Tukey multiple comparisons test) 
were comparable to those in the presence of BIBN 4096 
and capsaicin (P=0.39 and P=0.35, respectively, accord-
ing to a 1-way ANOVA followed by a Tukey multiple com-
parisons test; Figure 5). In addition, BIBN 4096 did not 
affect the NAPQI-mediated relaxations in the presence 
of AMG9810 (n=7; Figure 5). These results confirm 
comprehensively that this component of the relaxation 
Figure 3. N-acetyl-p-benzoquinone imine (NAPQI) relaxes preconstricted mesenteric arteries, which is attenuated by Kv7 
channel inhibition.
A, Representative isometric tension recordings showing the effect of increasing concentrations of NAPQI in rat mesenteric arteries 
preconstricted with 10 µmol/L methoxamine (•) in the (i) absence and (ii) presence of the Kv7 channel inhibitor, linopirdine (10 µmol/L). B, i, 
Mean data showing the effect of NAPQI in the absence (n=14) and presence of linopirdine (n=9) o the tension of preconstricted rat mesenteric 
arteries. B, ii, Linopirdine significantly attenuates the maximum relaxation (Rmax) for NAPQI (according to a Student unpaired t test, ***P<0.001).
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was due to CGRP release from the perivascular nerves 
and not a direct effect of NAPQI on the CGRP receptor.
We confirmed that CGRP receptor stimulation could 
lead to Kv7 channel activation by applying increasing 
concentrations of CGRP in the absence and presence 
of linopirdine. We also tested the effect of the KATP chan-
nel blocker glibenclamide because these channels have 
been implicated in CGRP-dependent relaxations.25 CGRP 
caused concentration-dependent relaxation of mesenteric 
artery segments, which was inhibited by linopirdine (Figure 
III in the Data Supplement). Glibenclamide had no effect on 
CGRP-dependent relaxations (Figure III in the Data Supple-
ment). Furthermore, glibenclamide had no effect on NAPQI-
induced relaxations (Figure IV in the Data Supplement).
AM404 Stimulates CGRP Release to elicit 
Vasorelaxations That Are Linopirdine-Sensitive
The second APAP metabolite, AM404, caused concen-
tration-dependent relaxation of preconstricted mesen-
teric artery segments (n=7; Figure 6). The Kv7 channel 
blocker, linopirdine, attenuated this relaxation (n=7; 
Rmax P=0.01 according to a 1-way ANOVA followed by 
a Dunnett multiple comparisons test; Figure 6); Appli-
cation of the CGRP receptor antagonist, BIBN 4096, 
fully inhibited AM404-induced relaxations (n=7; Rmax 
P=0.0007 according to a 1-way ANOVA followed by a 
Dunnett multiple comparisons test; Figure 6). Applica-
tion of 30 µmol/L AM404 in high K+-containing PSS 
had no effect (Figure I in the Data Supplement).Taken 
together, these data suggest that AM404 was eliciting 
its relaxation through CGRP release, which activates 
vascular Kv7 channels and other cAMP-dependent 
vasorelaxant mechanisms.
NAPQI Enhances Kv7.5 Channel Activity
Vascular smooth muscle cells express Kv7.4 and Kv7.5 
channels, which are important regulators of vascular 
tone.26,27 We tested whether NAPQI or AM404 were 
able to enhance Kv7.4 or Kv7.5 channels overexpressed 
in oocytes. At 1 µmol/L, NAPQI had no effect on Kv7.4 
Figure 4. N-acetyl-p-benzoquinone imine (NAPQI)-mediated relaxations are dependent on calcitonin gene-related peptide 
(CGRP) receptor activation as well as Kv7 channel activation.
A, Representative isometric tension recordings showing the effect of increasing concentrations of NAPQI in rat mesenteric arteries 
preconstricted with 10 µmol/L methoxamine (•; i) under control conditions, (ii) in the presence of the CGRP receptor antagonist, BIBN 4096, 
and (ii) in the presence of BIBN 4096 and the Kv7 channel inhibitor, linopirdine (10 µmol/L). B, i, Mean data showing the effect of NAPQI 
on changes in tension of preconstricted rat mesenteric arteries in control arteries (n=14), in the presence of BIBN 4096 (n=7) and in the 
presence of BIBN 4096 and linopirdine (n=7). B, ii, BIBN 4096 significantly attenuates the LogEC50 for NAPQI (according to an unpaired t 
test, ***P<0.001). B, iii, BIBN 4096 and BIBN 4096 with linopirdine attenuated the Rmax for NAPQI (according to a 1-way ANOVA followed 
by a Tukey multiple comparisons test, **P<0.01 and ***P<0.001).
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current density and no effect on Kv7.4 V0.5activation. Con-
versely, 100 µmol/L NAPQI increased Kv7.4 cur-
rents 20-fold at −60 mV and shifted Kv7.4 V0.5activation 
−19.1±2.7 mV (Figure 7A through 7C). Consistent with 
the effect on Kv7.4 V0.5activation, NAPQI hyperpolarised the 
EM of oocytes expressing Kv7.4 (Figure 7D). Kv7.4 cur-
rents were also augmented 4-fold at +40 mV by 100 
µmol/L NAPQI (Figure 7B).
In comparison, Kv7.5 exhibited even greater sensitiv-
ity to NAPQI, with 1 µmol/L increasing Kv7.5 currents 
4-fold at −60 mV and shifting the V0.5activation −10.1±1.4 
mV (Figure 7E through 7G). At 1 µmol/L, NAPQI 
hyperpolarised by −10 mV the EM of oocytes express-
ing Kv7.5 (Figure 7H). Strikingly, 100 µmol/L NAPQI 
resulted in potent augmentation of Kv7.5 currents even 
between −120 to −80 mV, increasing Kv7.5 currents 
100- to 130-fold (Figure 7E through 7G) and hyper-
polarising by >−20 mV the EM of oocytes expressing 
Kv7.5 (Figure 7H). Like Kv7.4, maximal Kv7.5 currents at 
+40 mV were also augmented (11-fold by 100 µmol/L 
NAPQI; Figure 7F).
We were unable to establish an accurate NAPQI 
EC50 value for Kv7.4 or Kv7.5 due to the nature of the 
dose-response curve, which suggests NAPQI is a highly 
efficacious Kv7.4 and Kv7.5 activator, but with a relatively 
high EC50 (Figure 7I). Heteromeric Kv7.4/Kv7.5 chan-
nels exhibited a NAPQI sensitivity that was intermediate 
between that of the respective homomers (Figure 7I).
Consistent with data in Figure 6, which suggested 
that Kv7 channel activation by AM404 was entirely 
indirect via perivascular nerve stimulation, AM404 had 
negligible effects on oocyte-expressed Kv7.4 and Kv7.5 
activity (Figure 7J) or voltage dependence (Figure 7K), 
as also evidenced by the lack of changes it induced in 
Kv7.4 or Kv7.5 current magnitude, across the voltage 
range (Figure 7L).
DISCUSSION
APAP is the most commonly used analgesic in the world. 
Apart from well-known dose-dependent hepatotoxicity, it 
is considered a safe drug; yet, the precise modes of action 
for various APAP metabolites are still unknown, and new 
targets are still being discovered.11–13 One such target 
revealed recently was the neuronal Kv7 channels, Kv7.2 
and Kv7.3, which are enhanced by the APAP metabolite 
Figure 5. N-acetyl-p-benzoquinone imine (NAPQI) relaxes preconstricted mesenteric arteries by stimulating calcitonin gene-
related peptide (CGRP) release.
Representative isometric tension recordings showing the effect of increasing concentrations of NAPQI in preconstricted (•) rat mesenteric 
arteries (A) pretreated with, and in the presence of capsaicin, and (B) in the presence of AMG9810. C, i, Mean data showing the effect 
of NAPQI on changes in tension of preconstricted rat mesenteric arteries in control arteries (n=14), in the presence of BIBN 4096 (n=7), 
capsaicin (n=7) and BIBN 4096 with capsaicin (n=7). C, ii, Mean data showing the effect of NAPQI on changes in tension of preconstricted 
rat mesenteric arteries in control arteries (n=14), in the presence of BIBN 4096 (n=7), AMG9810 (n=7) and BIBN 4096 with AMG9810 
(n=7). D, BIBN 4096, capsaicin, and AMG9810 all attenuated the LogEC50 for NAPQI significantly (according to a one-way ANOVA followed 
by a Tukey multiple comparisons test, **P<0.01 and ***P<0.001).
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NAPQI.14 In this study, we have found that Kv7 channel 
activation contributes to APAP-induced hypotension and 
that NAPQI, but not AM404, is able to enhance Kv7.4 
and Kv7.5 channels directly.
The Kv7 channel family of voltage-gated K+ channels 
exists of 5 isoforms encoded by the KCNQ1-5 genes 
(Kv7.1–Kv7.5), with each isoform having a characteris-
tic tissue distribution and function. In the vasculature, 
Kv7 channels, particularly, Kv7.4 and Kv7.5 channels, are 
important regulators of vascular tone.16–21 Kv7 channel 
activation in smooth muscle produces hyperpolarisation 
of the membrane potential, decreasing the open prob-
ability of the voltage-gated calcium channels, which ulti-
mately results in decreased Ca2+ entry and decreased 
contractility. Moreover, Kv7 channels in vascular smooth 
muscle are functional end points for numerous endog-
enous vasodilators. Agonists of Gs-coupled receptors, 
such as calcitonin-gene-related peptide (CGRP), iso-
prenaline, and adenosine, increase vascular Kv7 channel 
activity and promote vasodilation.28–33
APAP is available in intravenous form for inpatient 
management of acute pain. In the critically ill patients 
to which it is administered, intravenous APAP can 
cause iatrogenic hypotension, which hemodynamically 
compromises the patient, increasing mortality.4,5,9,34 
Up to 61% of patients treated with acetaminophen 
develop transient hypotension,5–8 which is also known 
to affect noncritically ill patients.35 The severity of the 
APAP-induced transient hypotension is highlighted by 
studies identifying >33% of patients that had APAP-
induced hypotension required therapeutic interven-
tion.6,9 The iatrogenic and molecular mechanisms of 
APAP-induced hypotension remain unknown, with 
decreases in both cardiac output and peripheral resis-
tance being implicated.4 In the present study, we found 
that intravenous administration of APAP to anesthe-
tized rats caused a transient decrease in mean arterial 
pressure of −17±2 mm Hg, similar to that described 
in humans.4,9 We were able to attenuate this hypoten-
sion with preinfusion and coinfusion of the Kv7 chan-
nel inhibitor, linopirdine. These findings suggest the 
APAP-induced hypotension is due to activation of 
the Kv7 channels on vascular smooth muscle, which 
would decrease total peripheral resistance. We did not 
observe any APAP-induced changes in heart rate or 
pulse pressure, suggesting that cardiac output is main-
tained and is not responsible for the hypotension we 
observed in the anesthetized rats.
Figure 6. N-arachidonoylphenolamine (AM404)–mediated relaxations are dependent on calcitonin gene-related peptide 
(CGRP) receptor activation.
A, Representative isometric tension recordings showing the effect of increasing concentrations of AM404 in rat mesenteric arteries 
preconstricted with 10 µmol/L methoxamine (•; i) under control conditions, (ii) in the presence of the Kv7 channel inhibitor, linopirdine (10 
µmol/L), and (iii) in the presence of the CGRP receptor antagonist, BIBN 4096. B, i, Mean data showing the effect of AM404 on changes 
in tension of preconstricted rat mesenteric arteries in control arteries (n=7), in the presence of linopirdine (n=7) and in the presence of BIBN 
4096 (n=7). B, ii, Linopirdine and BIBN 4096 attenuated the maximum relaxation (Rmax) for AM404 (according to a 1-way ANOVA followed 
by a Tukey multiple comparisons test, *P<0.05 and ***P<0.001).
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Using ex vivo segments of mesenteric artery, we were 
able to investigate thoroughly the Kv7 channel activation 
that occurs with APAP in vivo. We report that 2 differ-
ent APAP metabolites, AM404 and NAPQI, can induce 
CGRP release from CGRPergic perivascular nerves 
found in the adventitial layer of mesenteric arteries,24,36 
thereby relaxing preconstricted mesenteric arteries.24,36–38 
This relaxation was dependent predominantly, but not 
completely, on Kv7 channel activation. Several studies 
have shown that Kv7 channels are important downstream 
effectors of cAMP-mediated vasorelaxations.28–33 A study 
by Chadha et al29 found that CGRP-mediated dilation of 
rat middle cerebral arteries requires functional Kv7 chan-
nels, and in this study, we demonstrate that linopirdine 
attenuated CGRP relaxations in isolated rat mesenteric 
arteries. We also investigated whether KATP channels were 
indirectly involved in the NAPQI- and AM404-dependent 
relaxations, downstream of CGRP release,25 but found 
no effect of the KATP inhibitor, glibenclamide. This was in 
line with no effect of glibenclamide on CGRP relaxations, 
Figure 7. N-acetyl-p-benzoquinone imine (NAPQI) activates KCNQ4 and KCNQ5 channels.
A, Mean traces showing effects of NAPQI (1 vs 100 µmol/L, as indicated) on Kv7.4 (n=5–7). B, Raw and normalized (G/Gmax) Kv7.4 tail 
currents vs prepulse voltage relationships calculated from traces as in A in the presence (red) vs absence (black) of NAPQI (1 vs 100 µmol/L, 
as indicated; n=5–7). C, Effects of NAPQI (1 vs 100 µmol/L, as indicated) on Kv7.4 quantified as current fold-increase vs voltage (n=5–7). 
D, Effects of NAPQI (1 vs 100 µmol/L, as indicated) on resting membrane potential (EM) of unclamped Xenopus laevis oocytes expressing 
Kv7.4 (n=5–7). E, Mean traces showing effects of NAPQI (1 vs 100 µmol/L, as indicated) on Kv7.5 (n=5–10). F, Raw and normalized (G/
Gmax) Kv7.5 tail currents vs prepulse voltage relationships calculated from traces as in E in the presence (red) vs absence (black) of NAPQI 
(1 vs 100 µmol/L, as indicated; n=5–10). G, Effects of NAPQI (1 vs 100 µmol/L, as indicated) on Kv7.5 quantified as current fold-increase vs 
voltage (n=5–10). H, Effects of NAPQI (1 vs 100 µmol/L, as indicated) on resting membrane potential (EM) of unclamped X. laevis oocytes 
expressing Kv7.5 (n=5–10). I, Current fold-increase vs [NAPQI] for KCNQ4, Kv7.5, or heteromeric Kv7.4/ Kv7.5 channels at −60 mV (n=3–6). 
J, Mean traces showing effects of N-4-Hydroxyphenyl arachidonylamide (N-arachidonoylphenolamine [AM404]; 100 µmol/L) on Kv7.4 and 
Kv7.5 (n=5). K, Raw and normalized (G/Gmax) Kv7.4 and Kv7.5 tail currents vs prepulse voltage relationships calculated from traces as in J in 
the presence (blue) vs absence (black) of N-4-Hydroxyphenyl arachidonylamide (AM404; 100 µmol/L; n=5). L, Effects of N-4-Hydroxyphenyl 
arachidonylamide (AM404; 100 µmol/L) on Kv7.4 and Kv7.5 quantified as current fold-increase vs voltage (n=5). All error bars indicate SEM.
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which is supported by other studies.37,39 The results of our 
study support a role for Kv7 channel recruitment following 
CGRP receptor activation; however, we do not negate a 
role for other K+ channels in CGRP-mediated vasodila-
tions.37 In this study, we also found that NAPQI can acti-
vate Kv7 channels on the arterial smooth muscle directly 
to produce a vasorelaxation, which is seen at 10 µmol/L 
NAPQI in the presence of the CGRP antagonist, BIBN 
4096, after CGRP depletion with capsaicin and in the 
presence of the TRPV1 blocker, AMG9810. The ability of 
NAPQI to activate Kv7.4 and Kv7.5 channels directly was 
confirmed by 2-electrode voltage-clamp experiments on 
oocytes overexpressing these channels, whereas AM404 
had no effect on the overexpressed channels.
We suggest that NAPQI is the most likely metabolite 
to elicit the APAP-induced hypotension that was linopir-
dine-sensitive. The role of NAPQI, and not the alterna-
tive metabolite AM404, is supported by the current data, 
and it is unlikely that these effects are mediated by the 
other known metabolites of APAP (the glucuronic acid 
and sulfate adducts), as these have well established non-
toxic effects. NAPQI is a highly reactive electrophile and 
undergoes very ready adduction to proteins, particularly 
at Cys residues, which are the most reactive common 
nucleophiles on proteins and known to be very sensitive 
to modification. In this regard, it is worth noting that Kv7.4 
and 7.5 channels have a triad of reactive Cys residues 
that are known to be sensitive to modification,40 which 
could act as the potential site of NAPQI interaction. Such 
Cys residues would not be expected to be modified 
by the glucuronic acid, sulfate, or AM404 metabolites 
because of the poor reactivity of these species relative to 
NAPQI. Taken together, these striking findings show that 
NAPQI is the most likely APAP metabolite to cause vaso-
dilatation by directly activating Kv7 channels on vascular 
smooth muscle, whereas both NAPQI and AM404 are 
able to activate Kv7 channels indirectly through stimula-
tion of CGRP release from perivascular nerves.
APAP is taken in its oral form predominantly. When 
taken orally, APAP is metabolized extensively by the 
liver via 3 main hepatic pathways: glucuronidation, sulfa-
tion, and CYP450 (cytochrome P450) oxidation.41,42 At 
regular doses, between 80% to 90% of APAP is con-
jugated with glucuronic acid or sulfate to form nontoxic 
metabolites that can be excreted through the kidneys.43 
A minor component is metabolized by CYP450 enzymes 
to NAPQI, which is toxic. The most important of these 
CYP450 enzymes are CYP1A2, CYP2E1, and CYP3A4, 
although at high concentrations of APAP, metabolism 
via CYP2E1 predominates. Under normal therapeutic 
doses, NAPQI is detoxified rapidly in the liver by gluta-
thione and excreted through the bile.42,43 Thus, NAPQI 
is unlikely to have systemic hemodynamic effects when 
APAP is taken orally.
When administered intravenously, APAP needs 
to be metabolized outside of the liver to cause a Kv7 
channel–dependent decrease in total peripheral resis-
tance and concomitant decrease in blood pressure. 
The endothelial cells of the vascular wall contain sev-
eral CYP450 enzymes with prominent roles in vascular 
regulation, particularly those in the CYP 2 gene family 
(eg, CYP 2B, 2C8, 2C9, 2C10, and 2J2).44 We speculate 
that these CYP450 enzymes in the endothelium have the 
capacity to metabolize APAP to NAPQI, thereby result-
ing in a direct and indirect (through CGRP release) acti-
vation of Kv7 channels, as we showed in our myograph 
studies. One limitation of our study is that we have not 
investigated the role of endothelium CYP450 enzymes 
in APAP-induced hypotension. Future studies will clarify 
the role of these enzymes in generating NAPQI local-
ized throughout the vasculature to activate Kv7 channels 
and elicit the observed effects. In addition to CYP450 
enzymes, direct oxidation of APAP can lead to the for-
mation of radical species and NAPQI as a product spe-
cies. One such pathway of APAP oxidation involves the 
leukocyte-derived species myeloperoxidase,45 which is 
released in response to inflammatory stimuli and can 
lead to the generation of the powerful oxidants hypo-
chlorous acid, from chloride ions, hypobromous acid from 
bromide ions and hypothiocyanous acid from thiocyanate 
ions. This might prove to be a crucial pathway underlying 
NAPQI formation when APAP is administered intrave-
nously to critically ill patients that have systemic inflam-
mation, such as sepsis. It will be important for future 
studies to investigate whether systemic inflammation 
augments APAP-induced hypotension through increased 
NAPQI formation, which would provide a clear contraindi-
cation for the intravenous APAP in the critically ill.
Our data raise the possibility of a Kv7 channel blocker, 
such as linopirdine, being used to prevent the iatrogenic 
APAP-induced hypotension. A trial performed with linopir-
dine in Alzheimer disease patients reported elevations 
of liver function tests as the only adverse clinical event 
occurring significantly more often in linopirdine patients 
than in those receiving placebo.46 Although these data 
suggest linopirdine is well tolerated in patients, the 
effects of Kv7 channel blockers are not understood fully, 
particularly in the critically ill, which is a limitation of our 
study. Future work will investigate whether linopirdine is 
tolerated intravenously and if it is able to inhibit APAP-
induced hypotension in humans. Additionally, with the 
effect and target of NAPQI now identified in this study, 
future work could develop a novel, specific Kv7.4/7.5 
channel inhibitor that has a short half-life and is adminis-
tered intravenously with paracetamol.
In summary, we provide novel molecular insight to 
explain how intravenous APAP administration causes 
transient hypotension. Our findings demonstrate that 
direct and indirect activation of Kv7 channels by the 
APAP metabolite NAPQI can result in decreased arte-
rial tone, which can lead to a drop in blood pressure. 
Because patients receiving intravenous APAP are 
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usually critically ill, any severe hemodynamic changes, 
such as those associated with APAP, can be life-threat-
ening. Importantly, we show that blockade of vascular 
Kv7 channels with linopirdine can protect against a 
severe hypotensive episode, without affecting other 
cardiovascular parameters. Thus, we suggest that inhib-
iting Kv7 channels with intravenous linopirdine could be 
a novel therapy to prevent the potential life-threatening 
APAP-induced hypotension.
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